Continuous subcutaneous insulin infusion (CSII) may be an alternative to multiple daily injections (MDI) in pregestational diabetes during pregnancy. However, no clear improvement in obstetric and perinatal outcome has so far been established for CSII treatment.
Methods:
In a case-control study, 35 pregnancies treated with CSII and 64 pregnancies treated with MDI treatment were evaluated. Metabolic control and obstetric and perinatal outcome were compared.
Results:
Women in the CSII group improved their metabolic control (hemoglobin A1c before CSII, 7.83 ± 0.97%; 3–6 months after, 6.77 ± 0.61%; P < 0.05). Hemoglobin A1c before pregnancy was lower in the CSII group (6.62 ± 0.60%) than in the MDI group (7.59 ± 1.61%) (P < 0.05). No other significant differences, either in metabolic control of diabetes or in obstetric and perinatal outcome, were found.
Conclusions:
CSII treatment is safe in pregnancy, but it has not yet been associated with any improved pregnancy outcome.
Get full access to this article
View all access options for this article.
References
1.
MacintoshM, FlemingK, BaileyJ, DoyleP, ModderJ, AcoletD, GolightlyS, MillerA. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ, 2006; 333:177–183.
2.
JensenDM, DammP, Moelsted-PedersenL, OvensenP, WestergaardJG, MoellerM. Outcomes in type 1 diabetic pregnancies. Diabetes Care, 2004; 27:2819–2823.
3.
Diabetes and Pregnancy Group. French multicentric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care, 2003; 26:2990–2993.
4.
TempleRC, AldridgeVJ, MurphyHR. Prepregnancy care and pregnancy outcomes in women with type 1 diabetes. Diabetes Care, 2006; 29:1744–1749.
5.
Confidential Enquiry into Maternal and Child Health. Diabetes in Pregnancy: Are We Providing the Best Care? Findings of a National Enquiry: England, Wales and Northern Ireland. London: CEMACH, 2007.
6.
Confidential Enquiry into Maternal and Child Health. Pregnancy in Women with Type 1 and Type 2 Diabetes in 2002–03, England, Wales and Northern Ireland. London: CEMACH, 2005.
7.
GabbeSG. New concepts and applications in the use of the insulin pump during pregnancy. J Matern Fetal Med, 2000; 9:42–45.
8.
CoustanDR, ReeceEA, SherwinRS, RudolfMC, BatesSE, SockinSM, HolfordT, TamborlaneWV. A randomized clinical trial of the insulin pump vs. intensive conventional therapy in diabetic pregnancies. JAMA, 1986; 255:631–636.
9.
BottaRM, SinagraD, AngelicoMC, BompianiGD. [Comparison of intensified traditional insulin therapy and micropump therapy in pregnant women with type 1 diabetes mellitus]Minerva Med, 1986; 77:657–661.
10.
CartaQ, MeriggiE, TrossarelliGF, CatellaG, Dal MolinV, MenatoG, GagliardiL, MassobrioM, VitelliA. Continuous subcutaneous insulin infusion versus intensive conventional insulin therapy in type I and type II diabetic pregnancy. Diabet Med, 1986; 12:121–129.
11.
LaatikainenL, TeramoK, Hieta-HeikurainenH, KoivistoV, PelkonenR. A controlled study of the influence of continuous subcutaneous insulin infusion treatment on diabetic retinopathy during pregnancy. Acta Med Scand, 1987; 221:367–376.
12.
BurkartW, HankerJP, SchneiderHP. Complications and fetal outcome in diabetic pregnancy. Intensified conventional versus insulin pump therapy. Gynecol Obstet Invest, 1988; 26:104–112.
13.
LevenoKJ, FortunatoSJ, RaskinP, WilliamsML, WhalleyPJ. Continuous subcutaneous insulin infusion during pregnancy. Diabetes Res Clin Pract, 1988; 4:257–268.
14.
GabbeSG, HolingE, TempleP, BrownZA. Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. Am J Obstet Gynecol, 2000; 82:1283–1291.
15.
LapollaA, DalfraMG, MasinM, BruttomessoD, PivaI, CrepaldiC, TortulC, Dalla BarbaB, FedeleD. Analysis of outcome of pregnancy in type 1 diabetics treated with insulin pump or conventional insulin therapy. Acta Diabetol, 2003; 40:143–149.
16.
HieronimusS, CupelliC, BongainA, Durand-RevilleM, BerthierF, FenichelP. Pregnancy in type 1 diabetes: insulin pump versus intensified conventional therapy. Gynecol Obstet Fertil, 2005; 33:389–394.
17.
ChenR, Ben-HaroushA, Weissman-BrennerA, MelamedN, HodM, YogevY. Level of glycemic control and pregnancy outcome in type 1 diabetes: a comparison between multiple daily insulin injections and continuous subcutaneous insulin infusions. Am J Obstet Gynecol, 2007; 197:404.e1–404.e5.
18.
GiménezM, CongetI, NicolauJ, PericotA, LevyI. Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A case-control study. Acta Diabetol, 2007; 44:34–37.
19.
KernaghanD, FarrellT, HammondP, OwenP. Fetal growth in women managed with insulin pump therapy compared to conventional insulin. Eur J Obstet Gynecol, 2008; 137:47–49.
20.
MukhopadhyayA, FarrellT, FraserRB, OlaB. Continuous subcutaneous insulin infusion vs. intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol, 2007; 197:447–456.
21.
FarrarD, TuffnellDJ, WestJ. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev, 2007; (3):CD005542.
22.
Verdú MartinJ, Martin CaballeroC, García LópezG. Tablas Españolas de Pesos Neonatales Según edad Gestacional. Sociedad Española de Ginecología y Obstetricia, Sección de Medicina Perinatal. Barcelona: Ed Guidotti Pharma, 1998.
23.
WyattJW, FríasJL, HoymeHE, JovanovicL, KaajaR, BrownF, GargS, Lee-ParritzA, SeelyEW, KerrL, MattooV, TanM. IONS Study Group. Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy. Diabet Med, 2005; 22:803–807.
24.
García-EnguidanosA, CalleME, ValeroJ, LunaS, Domínguez RojasV. Risk factors in miscarriage: a review. Eur J Obstet Gynecol Reprod Biol, 2002; 102:111–119.
25.
BussL, TolstrupJ, MunkC, BergholtT, OttesenB, GrønbaekM, KjaerSK. Spontaneous abortion: a prospective cohort study of younger women from the general population in Denmark. Validation, occurrence, and risk determinant. Acta Obstet Gynecol Scand, 2006; 85:467–475.
26.
AdolfssonA, LarssonPG. Cumulative incidence of previous spontaneous abortion in Sweden in 1983–2003: a register study. Acta Obstet Gynecol Scand, 2006; 85:741–747.
27.
LorenzenT, PociotF, JohannesenJ, KristiansenOP, NerupJ. A population-based survey of frequencies of self-reported spontaneous and induced abortions in Danish women with Type 1 diabetes mellitus. Danish IDDM Epidemiology and Genetics Group. Diabet Med, 1999; 16:472–476.
